|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SDHC |
Gene summary for SDHC |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SDHC | Gene ID | 6391 |
| Gene name | succinate dehydrogenase complex subunit C | |
| Gene Alias | CYB560 | |
| Cytomap | 1q23.3 | |
| Gene Type | protein-coding | GO ID | GO:0006091 | UniProtAcc | Q99643 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6391 | SDHC | GSM4909281 | Human | Breast | IDC | 5.98e-18 | 4.72e-01 | 0.21 |
| 6391 | SDHC | GSM4909282 | Human | Breast | IDC | 1.54e-25 | 6.11e-01 | -0.0288 |
| 6391 | SDHC | GSM4909285 | Human | Breast | IDC | 5.85e-37 | 6.11e-01 | 0.21 |
| 6391 | SDHC | GSM4909286 | Human | Breast | IDC | 3.09e-02 | 6.55e-02 | 0.1081 |
| 6391 | SDHC | GSM4909288 | Human | Breast | IDC | 1.17e-03 | -1.75e-02 | 0.0988 |
| 6391 | SDHC | GSM4909291 | Human | Breast | IDC | 1.51e-03 | 3.58e-01 | 0.1753 |
| 6391 | SDHC | GSM4909293 | Human | Breast | IDC | 2.75e-14 | 3.45e-01 | 0.1581 |
| 6391 | SDHC | GSM4909296 | Human | Breast | IDC | 1.75e-08 | 1.97e-01 | 0.1524 |
| 6391 | SDHC | GSM4909297 | Human | Breast | IDC | 2.87e-08 | -4.99e-03 | 0.1517 |
| 6391 | SDHC | GSM4909298 | Human | Breast | IDC | 6.09e-12 | 4.07e-01 | 0.1551 |
| 6391 | SDHC | GSM4909301 | Human | Breast | IDC | 8.93e-04 | -2.80e-01 | 0.1577 |
| 6391 | SDHC | GSM4909302 | Human | Breast | IDC | 3.22e-05 | 3.14e-01 | 0.1545 |
| 6391 | SDHC | GSM4909306 | Human | Breast | IDC | 1.36e-17 | 4.71e-01 | 0.1564 |
| 6391 | SDHC | GSM4909307 | Human | Breast | IDC | 7.50e-16 | 4.53e-01 | 0.1569 |
| 6391 | SDHC | GSM4909308 | Human | Breast | IDC | 4.55e-33 | 7.17e-01 | 0.158 |
| 6391 | SDHC | GSM4909309 | Human | Breast | IDC | 3.75e-02 | 1.12e-01 | 0.0483 |
| 6391 | SDHC | GSM4909311 | Human | Breast | IDC | 1.77e-16 | -2.41e-01 | 0.1534 |
| 6391 | SDHC | GSM4909312 | Human | Breast | IDC | 2.63e-11 | 2.61e-01 | 0.1552 |
| 6391 | SDHC | GSM4909313 | Human | Breast | IDC | 3.96e-08 | 2.73e-01 | 0.0391 |
| 6391 | SDHC | GSM4909316 | Human | Breast | IDC | 3.26e-08 | 4.84e-01 | 0.21 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00460349 | Breast | Precancer | ATP metabolic process | 82/1080 | 277/18723 | 1.94e-36 | 5.19e-33 | 82 |
| GO:00061199 | Breast | Precancer | oxidative phosphorylation | 53/1080 | 141/18723 | 1.15e-29 | 2.04e-26 | 53 |
| GO:00090608 | Breast | Precancer | aerobic respiration | 58/1080 | 189/18723 | 5.69e-27 | 7.62e-24 | 58 |
| GO:00060918 | Breast | Precancer | generation of precursor metabolites and energy | 94/1080 | 490/18723 | 1.54e-25 | 1.64e-22 | 94 |
| GO:00453338 | Breast | Precancer | cellular respiration | 59/1080 | 230/18723 | 5.97e-23 | 5.32e-20 | 59 |
| GO:00159808 | Breast | Precancer | energy derivation by oxidation of organic compounds | 70/1080 | 318/18723 | 8.33e-23 | 6.37e-20 | 70 |
| GO:00196468 | Breast | Precancer | aerobic electron transport chain | 34/1080 | 87/18723 | 3.95e-20 | 2.64e-17 | 34 |
| GO:00427738 | Breast | Precancer | ATP synthesis coupled electron transport | 35/1080 | 95/18723 | 1.08e-19 | 5.76e-17 | 35 |
| GO:00427758 | Breast | Precancer | mitochondrial ATP synthesis coupled electron transport | 35/1080 | 95/18723 | 1.08e-19 | 5.76e-17 | 35 |
| GO:00229048 | Breast | Precancer | respiratory electron transport chain | 35/1080 | 114/18723 | 8.51e-17 | 3.26e-14 | 35 |
| GO:00229008 | Breast | Precancer | electron transport chain | 42/1080 | 175/18723 | 1.37e-15 | 4.59e-13 | 42 |
| GO:004603414 | Breast | IDC | ATP metabolic process | 85/1434 | 277/18723 | 6.42e-30 | 1.82e-26 | 85 |
| GO:000611913 | Breast | IDC | oxidative phosphorylation | 56/1434 | 141/18723 | 1.87e-26 | 3.53e-23 | 56 |
| GO:000906013 | Breast | IDC | aerobic respiration | 61/1434 | 189/18723 | 4.42e-23 | 6.27e-20 | 61 |
| GO:000609113 | Breast | IDC | generation of precursor metabolites and energy | 103/1434 | 490/18723 | 1.53e-21 | 1.74e-18 | 103 |
| GO:004533313 | Breast | IDC | cellular respiration | 62/1434 | 230/18723 | 5.98e-19 | 4.25e-16 | 62 |
| GO:004277313 | Breast | IDC | ATP synthesis coupled electron transport | 38/1434 | 95/18723 | 1.65e-18 | 9.36e-16 | 38 |
| GO:004277513 | Breast | IDC | mitochondrial ATP synthesis coupled electron transport | 38/1434 | 95/18723 | 1.65e-18 | 9.36e-16 | 38 |
| GO:001964613 | Breast | IDC | aerobic electron transport chain | 36/1434 | 87/18723 | 3.48e-18 | 1.80e-15 | 36 |
| GO:001598013 | Breast | IDC | energy derivation by oxidation of organic compounds | 73/1434 | 318/18723 | 8.70e-18 | 3.80e-15 | 73 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0471427 | Endometrium | EEC | Thermogenesis | 85/1237 | 232/8465 | 2.79e-17 | 7.05e-16 | 5.26e-16 | 85 |
| hsa0501236 | Endometrium | EEC | Parkinson disease | 117/1237 | 266/8465 | 5.97e-32 | 9.82e-30 | 7.32e-30 | 117 |
| hsa0501635 | Endometrium | EEC | Huntington disease | 120/1237 | 306/8465 | 3.86e-27 | 4.23e-25 | 3.15e-25 | 120 |
| hsa0502035 | Endometrium | EEC | Prion disease | 111/1237 | 273/8465 | 1.01e-26 | 8.27e-25 | 6.16e-25 | 111 |
| hsa0019035 | Endometrium | EEC | Oxidative phosphorylation | 70/1237 | 134/8465 | 6.33e-25 | 3.47e-23 | 2.59e-23 | 70 |
| hsa0520836 | Endometrium | EEC | Chemical carcinogenesis - reactive oxygen species | 94/1237 | 223/8465 | 4.11e-24 | 1.93e-22 | 1.44e-22 | 94 |
| hsa0501435 | Endometrium | EEC | Amyotrophic lateral sclerosis | 128/1237 | 364/8465 | 9.83e-24 | 4.04e-22 | 3.01e-22 | 128 |
| hsa0541535 | Endometrium | EEC | Diabetic cardiomyopathy | 86/1237 | 203/8465 | 2.59e-22 | 9.46e-21 | 7.05e-21 | 86 |
| hsa0501035 | Endometrium | EEC | Alzheimer disease | 126/1237 | 384/8465 | 2.25e-20 | 7.40e-19 | 5.52e-19 | 126 |
| hsa0493235 | Endometrium | EEC | Non-alcoholic fatty liver disease | 67/1237 | 155/8465 | 3.53e-18 | 1.06e-16 | 7.87e-17 | 67 |
| hsa0502235 | Endometrium | EEC | Pathways of neurodegeneration - multiple diseases | 140/1237 | 476/8465 | 9.49e-18 | 2.60e-16 | 1.94e-16 | 140 |
| hsa0471436 | Endometrium | EEC | Thermogenesis | 85/1237 | 232/8465 | 2.79e-17 | 7.05e-16 | 5.26e-16 | 85 |
| hsa0501239 | Esophagus | HGIN | Parkinson disease | 124/1383 | 266/8465 | 5.95e-32 | 9.70e-30 | 7.70e-30 | 124 |
| hsa0501630 | Esophagus | HGIN | Huntington disease | 129/1383 | 306/8465 | 6.81e-28 | 7.41e-26 | 5.88e-26 | 129 |
| hsa0502030 | Esophagus | HGIN | Prion disease | 117/1383 | 273/8465 | 4.15e-26 | 3.38e-24 | 2.69e-24 | 117 |
| hsa0501430 | Esophagus | HGIN | Amyotrophic lateral sclerosis | 140/1383 | 364/8465 | 2.13e-25 | 1.16e-23 | 9.19e-24 | 140 |
| hsa0502230 | Esophagus | HGIN | Pathways of neurodegeneration - multiple diseases | 153/1383 | 476/8465 | 1.22e-18 | 4.41e-17 | 3.50e-17 | 153 |
| hsa0501030 | Esophagus | HGIN | Alzheimer disease | 130/1383 | 384/8465 | 5.26e-18 | 1.71e-16 | 1.36e-16 | 130 |
| hsa05012114 | Esophagus | HGIN | Parkinson disease | 124/1383 | 266/8465 | 5.95e-32 | 9.70e-30 | 7.70e-30 | 124 |
| hsa05016113 | Esophagus | HGIN | Huntington disease | 129/1383 | 306/8465 | 6.81e-28 | 7.41e-26 | 5.88e-26 | 129 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SDHC | SNV | Missense_Mutation | c.436N>T | p.Pro146Ser | p.P146S | Q99643 | protein_coding | tolerated(0.2) | benign(0.014) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SDHC | SNV | Missense_Mutation | rs769177037 | c.149N>A | p.Arg50His | p.R50H | Q99643 | protein_coding | tolerated(0.06) | benign(0.382) | TCGA-AX-A0IZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SDHC | SNV | Missense_Mutation | rs749402669 | c.265G>A | p.Ala89Thr | p.A89T | Q99643 | protein_coding | tolerated(0.13) | benign(0.236) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| SDHC | SNV | Missense_Mutation | novel | c.140G>A | p.Gly47Asp | p.G47D | Q99643 | protein_coding | tolerated(0.17) | benign(0) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
| SDHC | SNV | Missense_Mutation | novel | c.275N>C | p.Leu92Pro | p.L92P | Q99643 | protein_coding | deleterious(0) | possibly_damaging(0.772) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SDHC | SNV | Missense_Mutation | novel | c.352N>C | p.Phe118Leu | p.F118L | Q99643 | protein_coding | deleterious(0.01) | benign(0.171) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
| SDHC | deletion | Frame_Shift_Del | novel | c.423delA | p.Gly142AlafsTer2 | p.G142Afs*2 | Q99643 | protein_coding | TCGA-EY-A5W2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| SDHC | SNV | Missense_Mutation | novel | c.312N>C | p.Lys104Asn | p.K104N | Q99643 | protein_coding | deleterious(0.01) | possibly_damaging(0.837) | TCGA-43-7656-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| SDHC | insertion | In_Frame_Ins | novel | c.179_179+1insTTGGTCTCTTCCCAT | p.Pro64_Met65insIleTrpSerLeuPro | p.P64_M65insIWSLP | Q99643 | protein_coding | TCGA-D6-A6EP-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | ||
| SDHC | SNV | Missense_Mutation | c.242N>A | p.Gly81Glu | p.G81E | Q99643 | protein_coding | deleterious(0.01) | probably_damaging(0.986) | TCGA-EJ-8472-01 | Prostate | prostate adenocarcinoma | Male | <65 | 8 | Unknown | Unknown | PD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |